Introduction {#Sec1}
============

POU-domain genes encode a large family of evolutionary conserved transcription factors that contain two characteristic DNA-binding domains, a homeobox and a POU domain. They play multiple roles during animal development (reviewed in Phillips and Luisi [@CR18]; Ryan and Rosenfeld [@CR24]). *Pou3f4* (also know as *Brn4*), one of the members of this family, has a complex and dynamic expression pattern in different vertebrate tissues such as the developing inner ear, brain, neural tube, kidney and pancreas (de Kok et al. [@CR8]; Heller et al. [@CR13]; Phippard et al. [@CR21]; Witta et al. [@CR26]). Studies in *Xenopus* indicate that *Pou3f4* (originally named *Xlpou2*) has the potential to transform epidermis to neural fate during early development (Witta et al. [@CR26]). Moreover, mouse models demonstrate that this gene is essential for inner ear development (Phippard et al. [@CR21]; Phippard et al. [@CR20]). In humans, several deletions, inversions and point mutations indicate that *POU3F4* is associated with the most common form of X-linked non-syndromic deafness, deafness type 3 (DFN3) (Bitner-Glindzicz et al. [@CR4]; de Kok et al. [@CR6], [@CR7], [@CR8], [@CR9]). Indeed, DFN3 patients show inner ear malformations that are similar to those found in mice lacking *Pou3f4* expression (Phippard et al. [@CR20], [@CR21]), indicating a conserved requirement of this gene for inner ear development in mammals and probably in other vertebrates as well.

In addition to coding sequences, some non-coding sequences display high conservation between evolutionary distant species. Their evolutionary conservation is suggested to underlie essential regulatory functions. Interestingly, the human *POU3F4* gene is located on the X chromosome, in a 3-Mb gene desert region enriched for highly conserved non-coding regions (HCNRs). Gene deserts enriched for HCNRs is a genomic feature characteristic of developmental genes with tightly regulated expression patterns (reviewed in Alonso et al. [@CR2]). Indeed, many different studies have shown that HCNRs are enriched in *cis*-regulatory elements (reviewed in Alonso et al. [@CR2]). Several DFN3 patients and families contain deletions that do not affect the transcribed region of *POU3F4* but instead remove different portions of DNA in the desert genomic region upstream of the gene (Cremers et al. [@CR5]; de Kok et al. [@CR8]) (Fig. [1](#Fig1){ref-type="fig"}a). The detailed genomic analysis of these deletions prompted to define a critical region for DFN3 \~920-kb upstream of the gene (de Kok et al. [@CR8]) and to propose the presence of *cis*-regulatory sequences essential for *POU3F4* expression in the developing inner ear in this critical region (de Kok et al. [@CR8]). Most of the identified microdeletions encompass a critical region of \~8 kb from a 13-kb *Eco*RI fragment (patient 2540) (Cremers et al. [@CR5]; de Kok et al. [@CR8]). Indeed, a recent report showed that, in mouse transgenic assays, a human 3.4-kb DNA fragment containing a HCNR located within this 13-kb fragment can promote expression in several inner ear structures derived from the otic mesenchyme (Ahn et al. [@CR1]). This includes the temporal bone, spiral ligament, and the mesenchyme underlying the sensory epithelium of the utricle, saccule and semicircular canals (Ahn et al. [@CR1]), most being structures affected in DFN3 patients or in mouse models for this disease (de Kok et al. [@CR7]; Phippard et al. [@CR20], [@CR21]). However, the expression pattern promoted by this HCNR did not fully recapitulate that of the endogenous *Pou3f4* gene (Ahn et al. [@CR1]). This, together with the fact that not all 5′ deletions remove the critical 13-kb interval (Cremers et al. [@CR5]; de Kok et al. [@CR8]), indicate that other important inner ear enhancers are likely to contribute to *POU3F4* expression in this territory.Fig. 1Localization of DFN3 deletions and HCNRs in the upstream genomic region of *POU3F4*. *Green arrows* show the position of the identified enhancers. **a** Deletion map within 1.5 Mb around *POU3F4* as reported previously (de Kok et al. [@CR8]; Cremers et al. [@CR5]). *Dashed lines* represent the deleted regions in each patient. The *red box* marks the 13-kb *Eco*RI fragment in which the 2540 8-kb deletion is located. **b** Vista view showing the distribution of HCNRs within 1-Mb upstream of *POU3F4*. Shown from *top* to *bottom* are mouse versus human, chicken versus human and *Xenopus tropicalis* versus human global alignments. *Coloured peaks* (*purple* coding, *pink* non-coding) indicate regions of at least 100 bp and 75% similarity. *Red dots* are HCNRs with no enhancer activity in *Xenopus* assays. *Green arrows* point at the HCNRs that showed enhancer activity (also shown with *green dots*). Their genomic positions are depicted in green. The *red box* marks the 13-kb *Eco*RI fragment in which the 2540 8-kb deletion is located. **c** Close-up of this 13-kb *Eco*RI fragment. Below is shown the new deletion identified in this work (*dotted line*). The *blue line* shows the region that was reported to have inner ear enhancer activity in mouse transgenic assays (Ahn et al. [@CR1])

Here, we report the enhancer survey of multiple HCNRs located in a region of 1-Mb upstream of *XenopusPou3f4* in both *Xenopus* and zebrafish by using transgenic assays. We identify three novel *Pou3f4* regulatory regions capable of activating expression in the developing otic vesicle, as well as in other *Pou3f4* expression domains. These novel regulatory regions are likely contributing to *POU3F4* inner ear expression and are therefore candidate regions to be affected in DFN3 patients. In addition, we identify a new DFN3 family that contains a minimal deletion of 3.9 kb that precisely removes the reported HCNR with inner ear enhancer activity within the 13-kb critical interval. These results support the idea that, despite the existence of other otic vesicle enhancers, this one is critical for *POU3F4* activity in the developing inner ear.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Family W06-205 with five affected males is shown in the pedigree from Fig. [4](#Fig4){ref-type="fig"}a. The hearing loss in four of them was already severe in childhood. For subject II.4 pure tone thresholds have never been determined. He was said to be born deaf but he developed some speech after big efforts of his mother. Individual II.6 is profoundly hearing impaired and did not develop speech. In patient III.2, the hearing loss is stable and severe to profound and speech development was very poor. Only for individuals IV.1 and IV.2, audiological data are available from childhood. The hearing loss of subject IV.1 was moderate at the age of 27 months and severe at 6 years. In individual IV.2, the hearing loss was less severe. He had moderate hearing loss at 10 and 12 years of age, with a significant air bone gap in the lower frequencies. He underwent stapes surgery at 12 years of age and stapes gusher occurred during surgery. There are no indications for hearing loss in any of the female mutation carriers of generations II--IV but audiometry has not been performed.

All patients or their legal representatives gave written informed consent for the study.

Genetic analyses {#Sec4}
----------------

Genomic DNA of family members was isolated from peripheral blood samples by a standard salting out procedure (Miller et al. [@CR17]). Analysis of 14 STR markers uniformly dispersed over the X chromosome was performed using standard methodology on an ABI 3130 DNA sequencer (Applied Biosystems, CA, USA). DNA sequencing of the complete *POU3F4* coding region was done by PCR amplification in overlapping fragments and sequencing using the same ABI sequencer. Sequences of primers employed to characterize the deletion in family W06-205 by amplification of fragments of the proximal region are provided in Supplementary Table 1. DMSO was added to 10% of the volume of the PCR for the amplicons 4 and 5. Amplification was performed with Phusion High-Fidelity DNA Polymerase (New England Biolabs, MA, USA). Primers have been designed with Primer3plus (<http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi>).

Functional reporter analyses in *Xenopus* and zebrafish {#Sec5}
-------------------------------------------------------

All HCNRs were selected with the vista browser (<http://pipeline.lbl.gov/cgi-bin/gateway2>) using the default parameters (regions of at least 100 bp and 70% similarity). HCNRs were amplified by PCR from *Xenopus tropicalis* genome using the primers listed in Supplementary Table 2. The PCR fragments were subcloned in PCR8/GW/TOPO (Invitrogen, CA, USA) vector and, using the gateway technology (Invitrogen, CA, USA), transferred to the corresponding destination enhanced green fluorescent protein (EGFP) reporter vectors recently described (Bessa et al. [@CR3]; Pittman et al. [@CR22]) for I-SceI or Tol2 mediated transgenesis in *Xenopus* or zebrafish, respectively. Embryos expressing GFP were analyzed by observation of fluorescence. *Xenopus* embryos were then fixed and processed for whole mount in situ hybridization to detect GFP mRNA.

*Xenopus* and zebrafish in situ hybridization {#Sec6}
---------------------------------------------

*EGFP* antisense RNA probes were prepared from cDNAs using digoxigenin (Roche, Basel, Switzerland) as label. *Xenopus* and zebrafish specimens were prepared, hybridized and stained as described (Harland [@CR12]; Tena et al. [@CR25]).

Results {#Sec7}
=======

Identification of novel *Pou3f4cis*-regulatory elements {#Sec8}
-------------------------------------------------------

We have examined the enhancer activity of multiple HCNRs present within 1-Mb upstream of *Pou3f4* by using *Xenopus* and zebrafish transgenic assays. The identified HCNRs were conserved from human to frog and located in the genomic region in which most DFN3 deletions map (Fig. [1](#Fig1){ref-type="fig"}a). We amplified 16 HCNRs (Supplementary Table 2) from the *Xenopus tropicalis* genome and cloned them in the PCR8/GW/TOPO vector. We have named these HCNRs according to the position of their human orthologous sequences, shown in kilobases, on the X chromosome of the NCBI human genome assembly 18. The cloned HCNRs were transferred to vectors compatible with SceI or Tol2 mediated transgenesis in *Xenopus* or zebrafish, respectively (Bessa et al. [@CR3]; Pittman et al. [@CR22]). In these vectors, the HCNRs are placed upstream of the proximal promoter of the *Xenopus* or zebrafish *gata2* gene driving the expression of the EGFP reporter gene. This promoter alone has no activity during embryogenesis neither in zebrafish nor *Xenopus*.

We first generated transient *Xenopus* transgenic embryos for all 16 HCNRs. From them, only five of these HCNRs (81675, 81728, 82478, 82637, and 82646; Fig. [1](#Fig1){ref-type="fig"}b) promoted reproducible reporter gene expression in different transgenic animals. All of them were active in a subset of regions expressing the endogenous *Pou3f4* gene (Fig. [2](#Fig2){ref-type="fig"}). We confirmed the enhancer activity of these five HCNRs by generating different stable zebrafish transgenic lines for each region by using the same *Xenopus* genomic sequences. For all five HCNRs, we observed equivalent reporter gene expression in zebrafish as compared to *Xenopus* (Fig. [2](#Fig2){ref-type="fig"}) in several domains, further confirming its specificity. In addition to element HCNR 81728, which is located 922-kb upstream of *POU3F4* and has recently been shown to be active in the otic capsule in mouse transgenic assays (Ahn et al. [@CR1]), the HCNRs located at positions 81675 (970-kb upstream), 82478 (170-kb upstream) and 82637 (12-kb upstream) promoted inner ear expression of EGFP in both *Xenopus* and zebrafish models (Fig. [2](#Fig2){ref-type="fig"}). The expression of the HCNR at 81675 was almost completely confined to the developing ear, with low background expression in the branchial arch and the eye in *Xenopus* embryos (Fig. [2](#Fig2){ref-type="fig"}a, b). In contrast, elements 82478 and 82637 also promoted EGFP expression in the midbrain/hindbrain boundary that is most prominently visible in the zebrafish transgenic lines (Fig. [2](#Fig2){ref-type="fig"}e--h). In addition, HCNR 82478 was also found to be active in the kidney and the pancreas (Fig. [2](#Fig2){ref-type="fig"}e, f, l). These tissues are all known to express *Pou3f4* (Fig. [2](#Fig2){ref-type="fig"}k) (de Kok et al. [@CR8]; Heller et al. [@CR13]; Phippard et al. [@CR21]; Witta et al. [@CR26]). Finally, the HCNR at position 82646 induced expression in the brain and spinal cord (Fig. [2](#Fig2){ref-type="fig"}i, j). This expression pattern is identical to that found in mouse transgenic assays with a 6-kb sequence from the mouse *Pou3f4* promoter region that contains the orthologous sequence (Heydemann et al. [@CR14]).Fig. 2Expression patterns promoted by different *Pou3f4* HCNRs in *Xenopus* and zebrafish transgenic assays. *Xenopus* embryos show in situ hybridization to detect EGFP mRNA in fixed transgenic animals while zebrafish embryos show EGFP in living transgenic specimens. All panels, except (**l**) that show a dorsal view, are lateral views of transgenic *Xenopus* (**a**, **c**, **e**, **g**, **i**) at stage 35 or transgenic zebrafish (**b**, **d**, **f**, **h**, **j**, **l**) at 36--72-h post fertilization (hpf). The position of the HCNRs in the human genome is shown in the *upper right corner* of each panel. Different tissues are pointed at with *coloured arrowheads*. *Blue* otic vesicle, *red* midbrain, *orange* hindbrain, *yellow* kidney and *purple* pancreas. Note the equivalent patterns promoted by each HCNR in *Xenopus* and zebrafish transgenic embryos. **k** Expression pattern of *XenopusPou3f4*

During inner ear development, *Pou3f4* is expressed in the periotic mesenchyme (Phippard et al. [@CR19], [@CR20]). To better characterize the expression pattern promoted by the new identified enhancers in the inner ear domain, we performed transverse sectioning of transgenic zebrafish embryos carrying the different enhancers at 65--75 h post fertilization. Enhancers at position 81675 and 82637, as well as the previous characterized at 81728, promote expression in the periotic mesenchyme (Fig. [3](#Fig3){ref-type="fig"}a, b, d, red arrows). Unexpectedly, all these enhancers were active in the otic epithelium (Fig. [3](#Fig3){ref-type="fig"}, white arrows), a tissue that seems to be devoid of *Pou3f4* expression (Phippard et al. [@CR19], [@CR20]). This was also occurring for the enhancer within HCNR 82478, which was not promoting expression in the periotic mesenchyme but strongly in the pronephros (Fig. [3](#Fig3){ref-type="fig"}c, yellow arrows). It is possible that the activity of all these enhancers in the otic epithelium in transgenic embryos reflects a low level of the endogenous *Pou3f4* expression in these cells. Alternatively, the activity in these regions may only be observed when the *Pou3f4* enhancers are not in their genomic context with other *cis*-regulatory elements. Interestingly, in mouse transgenesis assays, the enhancer at position 81728 also drives expression in some epithelial cells of the otic vesicle (Ahn et al. [@CR1]).Fig. 3Transverse sections at the level of the otic vesicle of 65--75 hpf embryos showing the expression patterns promoted by the different *Pou3f4* HCNRs in stable zebrafish transgenic lines. All panels show in situs hybridization to detect EGFP mRNA in fixed embryos from the different transgenic lines. Note that enhancers at positions 81675 (**a**), 81728 (**b**) and 82637 (**d**) promoted expression, although in somehow different areas, in the periotic mesenchyme (*red arrows*). In addition, all enhancers are active in the otic epithelium (*white arrows*) and enhancer 82478 (**c**) is, in addition, active in the developing kidneys (*yellow arrows*)

Characterization of a new DFN3 deletion {#Sec9}
---------------------------------------

To determine the possible association of deletions in HCNRs 81675, 81728, 82478, and 82637 with a DFN3 phenotype, we tested five index cases for deletions in these HCNRs. Mutation analysis of the protein-coding region of *POU3F4* did not reveal any putatively pathogenic mutations in these patients. Only in the proband of family W06-205 an indication for a deletion was obtained for one of the HCNRs, namely 81728 which is located \~920-kb upstream of *POU3F4* within the 13-kb *Eco*RI fragment known to harbour an \~8-kb deletion (patient 2540) (de Kok et al. [@CR8]). Family W06-205 of Greek origin presented with mixed hearing loss and segregation in the family was compatible with X-linked inheritance (Fig. [4](#Fig4){ref-type="fig"}a). Linkage analysis with STR markers across the X chromosome revealed linkage to a region containing the *POU3F4* gene (Xq21.1), with a maximum LOD score of 2.1. The characterization of the deletion was initiated by using five sets of primers for PCR (1--5; Supplementary Table 2) in patient II.6, his mother (I.2) and a control individual. The amplicons cover the 13-kb *Eco*RI fragment containing the deletion in patient 2540. All primer sets revealed a PCR fragment of the expected size in all three individuals except primer set 2 with which no amplification occurred in the individual II.6 (data not shown). Subsequently, three series of PCR primers (a--f, I--IV, and Δ; Supplementary Table 2) were developed to determine the breakpoint. With primer set Δ, we amplified a fragment of \~400 bp in the patient, a fragment of the same length in the carrier female and in addition a fragment of the expected size of \~4.3 kb in both the carrier and the control individual. By sequencing the 400-bp breakpoint spanning PCR fragment, the size of the deletion could be determined to be 3,902 bp (Fig. [4](#Fig4){ref-type="fig"}b) encompassing nucleotides 81727184--81731085 (Human genome assembly 18). This deletion segregated with the disease in the family as was tested by PCR with primer set Δ. In all patients and carriers, the 400-bp fragment could be amplified but not in healthy males or in spouses of the carriers (Fig. [4](#Fig4){ref-type="fig"}a). Carrier statuses of females who are not obligate carriers are not shown for privacy reasons. Primer set Δ did not reveal fragments of aberrant size in 100 normal hearing Greek males or in 50 control females. The 3.9-kb region that is deleted in affected males contains HNCR 81728 that is present in the 13-kb region that encompasses the smallest deleted region known so far (patient 2540) (Fig. [1](#Fig1){ref-type="fig"}c). Moreover, the reporter construct used in the paper by Ahn et al. ([@CR1]) contain a 3,370-bp genomic region that almost completely encompass the deletion we have identified.Fig. 4Genetic analysis of family W06-205. **a** Pedigree of family W06-205 and segregation of the deletion in the family. *Filled squares* represent DFN3 males. Δ deletion, + wildtype. The genotype of females who are not obligate carriers has not been indicated for privacy reasons. **b** Sequence chromatogram showing the deletion breakpoints in patient II.6. Above this chromatogram, the deletion is schematically indicated

Discussion {#Sec10}
==========

Breakpoint analysis of multiple deletions in different DFN3 patients suggests that *cis*-regulatory elements essential for *POU3F4* expression and inner ear development are located within \~900-kb upstream of the gene (de Kok et al. [@CR8]). Since most DFN3 deletions include the genomic fragment deleted in DFN3 patient 2540 (de Kok et al. [@CR8]), an essential enhancer should be present within the 13-kb region that contains this \~8-kb deletion. Accordingly, an inner ear enhancer at HCNR 81728 was recently reported (Ahn et al. [@CR1]). Here, we show that HCNR 81728 is functionally conserved in *Xenopus* and zebrafish. Moreover, the newly identified deletion, that precisely remove this HCNR and almost no additional neighbouring DNA, further demonstrates that this regulatory element is essential for *POU3F4* function during inner ear development. Nevertheless, the fact that there is one DFN3 deletion (II/7) that removes about 800-kb upstream of the gene but keeps the enhancer 81728 intact (Cremers et al. [@CR5]; de Kok et al. [@CR8]) (Fig. [1](#Fig1){ref-type="fig"}a), suggests that this enhancer, although essential, is not sufficient for *POU3F4* expression and function during ear development. In the original report (de Kok et al. [@CR8]), the II/7 deletion was uncorrectly depicted to be associated with a paracentric inversion which was later corrected (Cremers et al. [@CR5]). Indeed, the paracentric inversion is associated with the deletion G8314 and not with II/7, as shown here (Fig. [1](#Fig1){ref-type="fig"}a). The existence of additional otic vesicle enhancer is further supported by the expression promoted by HCNR 81728 which does not fully reproduce the *Pou3f4* pattern in the developing ear (Ahn et al. [@CR1]).

By analyzing the activity of 15 additional HCNRs present within 1-Mb upstream of *POU3F4*, we have found three novel inner ear enhancers at 970-, 170- and 12-kb upstream of the gene. This further suggests that the expression of *POU3F4* during inner ear development likely depends on several regulatory elements. In addition to the identified enhancers distributed along this vast 1-Mb genomic interval, others may exist in less conserved non-coding sequences or in regions not conserved at all, as has been shown for other loci (McGaughey et al. [@CR16]). The contribution of enhancers other than HCNR 81728 to *POU3F4* function during inner ear development may be significant, as can be inferred from deletion II/7 (Fig [1](#Fig1){ref-type="fig"}a). Evaluation of the clinical information provided for family W06-205 and the families with larger and overlapping or non-overlapping deletions did not reveal indications for a correlation between the severity of the hearing loss and the size of the deletion and/or the number of the ear HCNRs located in the deletion. This is further corroborated by the differences in the severity of the hearing impairment between affected males in family W06-205. Also, the hearing loss in family II/7 in which HCNR 81728 is present was described to be severe in all affected males with no or minimal speech development (Robinson et al. [@CR23]). Therefore, we can conclude that the presence of HCNR 81728 is essential but not sufficient for normal ear function.

Some of the studied enhancers not only promote expression in the developing inner ear but also in other *Pou3f4* expressing tissues such as the brain, kidney and pancreas. In addition, we have confirmed the presence of a neural enhancer in a HCNR positioned at 3-kb upstream of the gene, which was previously detected in mouse transgenic assays (Heydemann et al. [@CR14]). These results indicate that, as has been found for many other developmental genes (see for example de la Calle-Mustienes et al. [@CR10] and Jeong et al. [@CR15]), the dynamic *Pou3f4* expression pattern is determined by multiple *cis*-regulatory elements, being some of them partially redundant.

Why developmental genes, such as *POU3F4*, often possess multiple *cis*-regulatory elements that promote expression in partially overlapping domains? A recent report demonstrates that, in *Drosophila*, redundant enhancers become essential under stressing conditions. These results strongly suggest that redundant *cis*-regulatory elements contribute to phenotypic robustness under environmental and genetic variability (Frankel et al. [@CR11]). Therefore, the novel regulatory elements that are likely to contribute to the expression of *POU3F4* in the inner ear may well carry small deletions or point mutations in DFN3 patients in which no *POU3F4* point mutations, deletions or major genomic rearrangements have been detected so far.

Electronic supplementary material {#AppESM1}
---------------------------------

Below is the link to the electronic supplementary material.

###### 

Supplementary material 1 (DOC 116 kb)

We are most grateful to S. M. Sato for the *XenopusPou3f4* probe and we wish to thank members of family W06-205 for their participation in this study. This work was supported by grants from the Spanish Ministry of Education and Science (BFU2007-60042/BMC, Petri PET2007_0158, CSD2007-00008) and Junta de Andalucía (Proyecto de Excelencia CVI-3488) to JLG-S, and the Oticon Foundation (Denmark) to MBP. CABD is institutionally supported by CSIC, Universidad Pablo de Olavide and Junta de Andalucía.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
